Table 1.

Specificity, designation, and transduction efficacy of T-cell lines and clones used in this study

T cells/TIL/Clone*	Specificity †	Restriction ‡	Transduced with	Designated	Transduction efficacy (%)§
PBL-T1	NA||	NA	MIG	PT1-G	55
			MIG-Bcl	PT1-B	40
PBL-T2	NA	NA	MIG	PT2-G	22
			MIG-Bcl	PT2-B	39
TIL (1931-2F4)	MART-1 (27-35)	HLA-A2	MIG	1931-G	15
			MIG-Bcl	1931-B	25
TIL (1749)	MART-1 (27-35)	HLA-A2	MIG	1749-G	24.4
			MIG-Bcl	1749-B	35
Cl-2 1290 (CD4)	KI-67	DR-16	MIG	Cl-2-G	13
			MIG-Bcl	Cl-2-B	19.4
Cl-8-1541 (CD4)	Tyrosinase-related protein-2	DR-15	MIG	Cl-8-G	7.2
			MIG-Bcl	Cl-8-B	14.5
D4F12 (CD8)	GP100 (209-217)	HLA-A2	MIG	D4-G	20
			MIG-Bcl	D4-B	25
C22 (CD8)	Aim-1	HLA-A2	MIG	C22-G	14.2
			MIG-Bcl	C22-B	28.5

^*Two different peripheral blood lymphocyte-derived T-cell lines from healthy donors (PBL-T1 and PBL-T2) and two different TIL lines as well as four different tumor-specific T-cell clones (two clones are MHC-I restricted and two clones are MHC-II restricted) were used in this study.

^†Specificity is tested by the ability of the indicated cell line or clone to respond to target cell line that was either loaded with the indicated peptide(or controls) or transfected with the indicated antigen (or control antigens). Response was detected by measuring the IFN-γ that was secreted into the supernatant by specific ELISA.

^‡Restriction is determined by using allele-specific transfectants and blocking by antibodies.

^§Transduction efficacy measured by the percentage of GFP-positive T cells 1 week after the transduction with retroviruses.

^||Not applicable.